Michel Faure

Dr. Faure received his Ph.D. in Molecular Biology from Université Paris-Sud, Orsay (France) and did a postdoc at Columbia University. He then took a position at the CNRS in France and afterwards returned to the US for a second postdoc at UCSF. There Dr. Faure worked in Professor Henry Bourne’s lab, where he made several key contributions to the understanding of the cross-talk between GPCRs and the MAPK pathway. He then joined SUGEN, a pioneer in the field of kinase inhibitors, where he led several early drug discovery projects in oncology. He later joined Chiron/Novartis in Emeryville where his responsibilities included defining and implementing biomarker and patient stratification strategies for oncology drug discovery projects. He also managed several outside collaborations, including the procurement and validation of tool antibodies. Dr. Faure brings more than twenty years of biopharmaceutical research experience in oncology drug discovery. He founded Ensigna Biosystems, Inc. in March 2014 because he understands how the most advanced molecular pathology techniques are essential to the development of targeted therapies and the implementation of personalized medicine.